ScholarIQanswers from OpenAlex
Hepatocellular Carcinoma Treatment and Prognosis
TopicLeading institutions, researchers & key papers
Hepatocellular Carcinoma Treatment and Prognosis is a topic indexed in ScholarIQ from OpenAlex.
What is known about Hepatocellular Carcinoma Treatment and Prognosis?
ScholarIQrecord summary
This cluster of papers focuses on the management, diagnosis, and treatment of hepatocellular carcinoma (HCC), also known as liver cancer. It covers various aspects including clinical practice guidelines, radiofrequency ablation, use of sorafenib, liver resection, and survival rates.
How many works does Hepatocellular Carcinoma Treatment and Prognosis have?
ScholarIQindexed works
Hepatocellular Carcinoma Treatment and Prognosis has 805 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Hepatocellular Carcinoma Treatment and Prognosis?
ScholarIQopenalex
The OpenAlex for Hepatocellular Carcinoma Treatment and Prognosis is on the source record.
What are the most-cited papers on Hepatocellular Carcinoma Treatment and Prognosis?
ScholarIQmost cited works
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach, Laura Kulik, Richard S. Finn, Claude B. Sirlin, Michaël Abécassis, Lewis R. Roberts, Andrew X. Zhu, M. Hassan Murad, Jorge A. Marrero
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar, Jamil Asselah, Jean‐Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita
Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS)
Nuh N. Rahbari, O. James Garden, Robert Padbury, Mark E. Brooke‐Smith, Michael Crawford, René Adam, Moritz Koch, Masatoshi Makuuchi, Ronald P. DeMatteo, Christopher Christophi, Simon Banting, Val Usatoff, Masato Nagino, Guy J. Maddern, Thomas J. Hugh, Jean‐Nicolas Vauthey, Paul D. Greig, Myrddin Rees, Yukihiro Yokoyama, Sheung Tat Fan, Yuji Nimura, Joan Figueras, Lorenzo Capussotti, Markus W. Büchler, Jürgen Weitz
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata, Ann‐Lii Cheng, Norihiro Kokudo, Masatoshi Kudo, Jeong Min Lee, Jidong Jia, Ryosuke Tateishi, Kwang‐Hyub Han, Yoghesh K. Chawla, Shuichiro Shiina, Wasim Jafri, Diana A. Payawal, Takamasa Ohki, Sadahisa Ogasawara, Pei‐Jer Chen, Cosmas Rinaldi Adithya Lesmana, Laurentius A. Lesmana, Rino Alvani Gani, Shuntaro Obi, A. Kadir Dökmeci, Shiv Kumar Sarin
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
Vincenzo Mazzaferro, Josep M. Llovet, Rosalba Miceli, Sherrie Bhoori, Marcello Schiavo, Luigi Mariani, Tiziana Camerini, Sasan Roayaie, Myron Schwartz, Gian Luca Grazi, René Adam, P. Neuhaus, Mauro Salizzoni, Jordi Bruix, Alejandro Forner, Luciano De Carlis, Umberto Cillo, Andrew K. Burroughs, Roberto Troisi, Massimo Rossi, Giorgio Enrico Gerunda, Jan Lerut, Jacques Belghiti, I. Boin, Jean Gugenheim, Fedja A. Rochling, Bart van Hoek, Pietro Majno
Where is Hepatocellular Carcinoma Treatment and Prognosis research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Hepatocellular Carcinoma Treatment and Prognosis is open access?
ScholarIQopen access share
60%OPEN ACCESS